Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
Yi‐Long Wu, Rafał Dziadziuszko, Jin Seok Ahn, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 14, pp. 1265-1276
Closed Access | Times Cited: 133

Showing 1-25 of 133 citing articles:

Non-small-cell lung cancer
Lizza E.L. Hendriks, Jordi Remón, C. Faivre‐Finn, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 43
Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer
Jonathan Spicer, Tina Cascone, Murry W. Wynes, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 10, pp. 1373-1414
Open Access | Times Cited: 25
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
Jonathan Spicer, Marina Chiara Garassino, Heather A. Wakelee, et al.
The Lancet (2024) Vol. 404, Iss. 10459, pp. 1240-1252
Closed Access | Times Cited: 22
Integrated bioinformatics and experimental analysis of CHAF1B as a novel biomarker and immunotherapy target in LUAD
Wei Du, Xiaowei Wu, Qing‐Feng Li, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches
Lorenzo Foffano, Elisa Bertoli, Martina Bortolot, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 583-583
Open Access | Times Cited: 1
Impact of histopathological subtypes on invasive lung adenocarcinoma: from epidemiology to tumour microenvironment to therapeutic strategies
Shaowei Xin, Miaomiao Wen, Yahui Tian, et al.
World Journal of Surgical Oncology (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC
Allison E.B. Chang, Andrew J. Piper-Valillo, Raymond H. Mak, et al.
The Oncologist (2024) Vol. 29, Iss. 7, pp. 609-618
Open Access | Times Cited: 7
Lung Cancer Research and Treatment: Global Perspectives and Strategic Calls to Action
May-Lucie Meyer, S. Peters, Tony Mok, et al.
Annals of Oncology (2024)
Closed Access | Times Cited: 7
Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies
Pernelle Lavaud, Martina Bortolot, Lodovica Zullo, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2779-2779
Open Access | Times Cited: 5
Developing a Rhodium(III) Complex to Reprogram the Tumor Immune and Metabolic Microenvironments: Overcoming Multidrug Resistance and Metastasis in Non-Small Cell Lung Cancer
Wenjuan Li, Shanhe Li, Minghui Zhu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 19, pp. 17243-17258
Closed Access | Times Cited: 4
Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives
Claudia Parisi, Pamela Abdayem, Marco Tagliamento, et al.
Cancer Treatment Reviews (2024) Vol. 131, pp. 102845-102845
Closed Access | Times Cited: 4
Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer
Stephanie P.L. Saw, Wen‐Zhao Zhong, Rui Fu, et al.
Lung Cancer (2025) Vol. 200, pp. 108076-108076
Open Access
Actualités dans le cancer broncho-pulmonaire : traitements médicaux
Gérard Zalcman
Bulletin de l Académie Nationale de Médecine (2025)
Closed Access
Harnessing cell-surface CD26 proteolysis-targeting chimeras for molecular targeted therapy against non-small cell lung cancer
Qiuyu Gong, Guangjian Zhang, Bohao Liu, et al.
Research Square (Research Square) (2025)
Closed Access
Matters of the Heart: Cardiotoxicity Related to Target Therapy in Oncogene-Addicted Non-Small Cell Lung Cancer
Sara Torresan, Martina Bortolot, Elisa De Carlo, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 554-554
Open Access
Advances in adjuvant therapy for operable N2 non-small cell lung cancer: a narrative review
Lei Liu, Yan‐Ping Mao, Leilei Guo, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Burdens of Tracheal, Bronchus, and Lung Cancer From 1990 to 2021 in China Compared to the Global Projection of 2036: Findings From the 2021 Global Burden of Disease Study
Y L Chen, Qingpeng Zeng, Muyu Li, et al.
Thoracic Cancer (2025) Vol. 16, Iss. 2
Open Access
Proposal of real-world solutions for the implementation of predictive biomarker testing in patients with operable non-small cell lung cancer
Paul Hofman, Petros Christopoulos, Nicky D’Haene, et al.
Lung Cancer (2025), pp. 108107-108107
Closed Access
Salvage Surgery for Epidermal Growth Factor Receptor-Mutant Lung Cancer With Osimertinib Resistance: A Case Report
Shinya Otsuka, Yutaro Nagano, Makoto Shioya, et al.
Cureus (2025)
Open Access
Stage IIIA Non‐Small Cell Lung Cancer Treatment and Outcomes: A Single Institution Retrospective Analysis
Richard Duan, Michelle Kwan, Avram Kordon, et al.
Thoracic Cancer (2025) Vol. 16, Iss. 3
Open Access
Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studies
Hiroaki Akamatsu, Tomomi Nishikawa, Yuriko Takeda, et al.
Lung Cancer (2025) Vol. 201, pp. 108437-108437
Open Access
Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements
Kyuhwan Kim, Kyu Yean Kim, Hye Seon Kang, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Unforeseen nodal upstaging in patients undergoing segmentectomy without frozen section: a multicenter retrospective cohort study
Lin Huang, Alessandro Brunelli, Demetrios Stefanous, et al.
Surgical Endoscopy (2025)
Open Access
A clinician’s perspective: what tumor-organoid researchers ought to know
Jeong Uk Lim
Organoid (2025) Vol. 5, pp. e1-e1
Open Access
Association between ALK Tyrosine Kinase Inhibitor and the Risk of Interstitial Lung Disease and Pneumonitis in Non-Small Cell Lung Cancer Patients: A Systematic Review
Shuimei Sun, Rui Zhang, Songsong Tan, et al.
(2025)
Closed Access
Page 1 - Next Page

Scroll to top